• Airway LMP7 Protects Against Rhinovirus Infection

  2026-08-07

  The reference study identifies airway epithelial LMP7 as an active regulator of both rhinovirus burden and inflammatory resolution, rather than merely a component of antigen-processing machinery. By combining inducible epithelial-specific knockout mice with CRISPR-Cas9-edited human airway cells, the authors connect LMP7 to A20/TNFAIP3 induction and provide a framework for studying epithelial immunoproteasome function in respiratory disease.

• Translational Neuroepigenetics: Signal Amplification for m6A

  2026-08-07

  This thought-leadership article explores how the HyperFluor™ 488 Goat Anti-Mouse IgG (H+L) Antibody from APExBIO is redefining sensitivity and reproducibility in neuroepigenetic research, with a focus on m6A-mediated memory regulation. By integrating mechanistic insights from the latest studies on YTHDF2 and m6A mRNA turnover, we offer strategic guidance for translational scientists aiming to bridge bench discoveries with clinical impact. The article details protocol parameters, competitive landscape, translational relevance, and a forward-looking outlook, while also referencing and building upon the latest content assets in the field.

• Epoxomicin: Precision Proteasome Inhibitor for Pathway Resea

  2026-08-06

  Epoxomicin stands out as a benchmark selective, irreversible proteasome inhibitor, empowering researchers to dissect protein degradation, inflammation, and neurodegenerative processes with unparalleled specificity. This guide details stepwise workflows, advanced applications, and actionable troubleshooting tips to maximize reproducibility and impact in ubiquitin-proteasome pathway research.

• MG-132 (Z-LLL-al): Proteasome Inhibitor for Apoptosis & Cell

  2026-08-06

  MG-132 (Z-LLL-al) is a potent, selective peptide aldehyde proteasome inhibitor used in apoptosis assay and cell cycle arrest studies. With nanomolar IC50 for proteasome inhibition and proven efficacy across cancer cell lines, MG-132 enables mechanistic dissection of the ubiquitin-proteasome system, oxidative stress, and cell death pathways.

• HyperFluor 488 Goat Anti-Mouse IgG: Applied Immunofluorescen

  2026-08-05

  HyperFluor™ 488 Goat Anti-Mouse IgG (H+L) Antibody from APExBIO elevates sensitivity and reproducibility in immunofluorescence and cytometry through robust fluorescence and affinity purification. This article translates recent mitochondrial dynamics research and real-world troubleshooting into actionable, high-performance assay workflows.

• Meropenem Trihydrate: Carbapenem Antibiotic in Resistance Re

  2026-08-05

  Meropenem trihydrate empowers advanced experimental workflows for dissecting carbapenem resistance and optimizing infection models. Discover how this carbapenem antibiotic, supplied by APExBIO, translates into robust metabolomics, precision microbiology, and troubleshooting for gram-negative and gram-positive bacterial studies.

• Metabolomics Distinguishes Carbapenemase-Producing Enterobac

  2026-08-04

  This study leverages LC-MS/MS-based metabolomics to rapidly and accurately distinguish carbapenemase-producing Enterobacterales from non-producers using metabolic signatures. The findings highlight key metabolic pathways involved in resistance, suggesting potential biomarkers for faster clinical diagnostics and deeper mechanistic understanding.

• ONX-0914 (PR-957): Precision Immunoproteasome Inhibition for

  2026-08-04

  ONX-0914 (PR-957) delivers unmatched selectivity for LMP7, enabling precise modulation of cytokine production in disease-relevant models. This guide details optimized workflows, troubleshooting strategies, and novel applications, anchored in recent advances in immunoproteasome biology.

• Central Circuits of Opioid-Induced Mechanical Hypersensitivi

  2026-08-03

  Yin et al. (2024) delineate a central brain-to-spinal opioid circuit mediating morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. The study identifies disruption of specific neuronal pathways as a key mechanism, offering new targets for chronic pain and opioid pharmacology research.

• Structural Advances in Silybin Chemistry from Milk Thistle

  2026-08-03

  The comprehensive review by Křen et al. systematically dissects the structural chemistry, stereochemistry, and derivatization strategies of silybin, the main flavonolignan in milk thistle extract. These advances underpin more precise applications of silymarin in research models of oxidative stress, hepatocellular carcinoma, and metabolic regulation, while also clarifying important limitations in formulation and transferability.

• Talabostat Mesylate: Protocols and Innovations for DPP4 Inhi

  2026-08-02

  Talabostat mesylate (PT-100) unlocks precision for dissecting DPP4 and FAP functions in cancer research and skin immunity, with actionable protocol enhancements. Insights from the latest keratinocyte inflammasome study guide model selection, troubleshooting, and advanced workflow design.

• hiPSC-Derived Intestinal Organoids Advance Pharmacokinetics

  2026-08-01

  This study introduces a robust protocol for generating intestinal organoids from human pluripotent stem cells, establishing a physiologically relevant in vitro model for pharmacokinetic analysis. The approach overcomes limitations of traditional models, enabling more accurate evaluation of drug metabolism and absorption in preclinical research.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-07-31

  Schwartz's dissertation advances in vitro evaluation of anti-cancer drugs by dissecting the nuanced relationship between growth inhibition and cell death. This work clarifies how distinct quantitative metrics capture different mechanisms of drug action, offering a more precise framework for interpreting responses in preclinical oncology studies.

• PF-562271 HCl: Precision FAK/Pyk2 Inhibitor for Tumor Resear

  2026-07-31

  PF-562271 HCl empowers cancer researchers with highly selective, ATP-competitive inhibition of FAK/Pyk2, enabling robust investigation of tumor growth, metastasis, and microenvironment modulation. This guide distills best-practice workflows, troubleshooting insights, and cross-study applications to maximize the value of this APExBIO tool compound.

• MG-132 (Z-LLL-al): Applied Workflows in Apoptosis & Cell Cyc

  2026-07-30

  MG-132 (Z-LLL-al) stands out as a robust, cell-permeable proteasome inhibitor for dissecting apoptosis, cell cycle regulation, and oxidative stress in cancer biology. This article delivers actionable workflows, troubleshooting tactics, and translates the latest mechanistic insights—empowering researchers to maximize reproducibility and mechanistic depth in proteostasis studies.

16370 records 1/1092 page Next 12345 下5页 Last page